Result of AGM

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                                 Result of AGM                                 

Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting held
earlier today, all resolutions put to shareholders were duly passed.

For further information please contact:

Bioventix plc              Chief Executive Officer    Tel: [phone]       
Peter Harrison                                                                 
                                                                               
finnCap Ltd                Corporate Finance          Tel: [phone]       
Geoff Nash/Simon Hicks     Corporate Broking                                   
Stephen Norcross                                                               

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.